Layaisa (Drospirenone, Ethinylestradiol)

The drospirenone component acts as a progestin, while ethinylestradiol is an estrogen. Together they suppress the release of luteinizing hormone and follicle‑stimulating hormone from the pituitary, preventing ovulation, and they also thicken cervical mucus and alter the endometrium to reduce the chance of implantation.

The dosing regimen for Layaisa is determined by the prescribing healthcare professional. Typically, it is taken once daily at the same time for a 21‑day active‑pill sequence followed by a 7‑day placebo interval, but the exact schedule should follow the prescriber’s instructions.

Layaisa is classified as pregnancy category X, meaning it must not be used during pregnancy because it can harm the fetus. It is also not recommended while breastfeeding, as hormonal exposure may affect milk production and infant development. Women should discontinue use if they become pregnant.

To order Layaisa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Layaisa contains drospirenone, a progestin with anti‑mineralocorticoid activity, which may reduce water retention compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly, especially regarding weight gain and blood‑pressure effects.

Layaisa tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children to maintain product stability and potency.

Layaisa is taken orally, once daily, preferably at the same time each day. The typical regimen includes 21 consecutive active tablets followed by a 7‑day placebo interval, during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their healthcare provider.

Serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, severe allergic reactions, and liver dysfunction. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid using Layaisa.

Layaisa is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, have a history of thromboembolic events, uncontrolled hypertension, severe liver disease, or who are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.